By admin 
In a move that escalates the long-simmering tensions between the pharmaceutical industry and safety-net healthcare providers, a bipartisan coalition of congressional lawmakers has formally petitioned the Department of Health and Human Services (HHS) to intervene in a burgeoning dispute involving Eli Lilly and Company. The lawmakers are calling on HHS Secretary Robert F. Kennedy Jr. to exercise federal authority to compel the Indianapolis-based drugmaker to reinstate mandated price breaks for hospitals participating in the federal 340B drug discount program. This demand follows Eli Lilly’s recent decision to withhold discounts from dozens of large hospital systems that have refused to comply with the company’s new and controversial data-sharing requirements.
The 340B program, established by Congress in 1992, requires pharmaceutical manufacturers to provide outpatient drugs to eligible healthcare organizations—known as "covered entities"—at significantly reduced prices. These entities typically include providers that serve a high volume of low-income and uninsured patients, such as Federally Qualified Health Centers (FQHCs), specialized clinics, and "disproportionate share" hospitals. The program was designed to allow these providers to "stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services," according to the Health Resources and Services Administration (HRSA), the agency within HHS that oversees the program.
However, the program has become a battlefield for litigation and lobbying over the last decade. Pharmaceutical companies argue that the program has expanded far beyond its original intent, leading to "duplicate discounts" where they are forced to pay both a 340B discount and a Medicaid rebate on the same unit of a drug—a practice explicitly prohibited by federal law. Eli Lilly’s latest maneuver represents a significant escalation in this conflict. Last month, the company announced it would stop offering 340B discounts to approximately 50 of the nation’s largest hospital systems because these institutions refused to submit detailed claims data through a third-party platform. Lilly maintains that this data is essential to verify that discounts are not being improperly duplicated.
The letter sent to Secretary Kennedy, signed by dozens of representatives from both sides of the aisle, argues that Eli Lilly’s actions are a direct violation of the 340B statute. The lawmakers contend that the law does not grant manufacturers the authority to impose unilateral conditions, such as data-sharing mandates, on the receipt of statutory discounts. "Eli Lilly is effectively holding safety-net providers hostage by demanding data that they are not legally required to provide as a condition of receiving the discounts they are entitled to under the law," the letter states. "By cutting off these price breaks, the company is jeopardizing the financial stability of hospitals that serve our most vulnerable populations."
The timing of this confrontation is particularly sensitive given the political landscape of 2026. With Robert F. Kennedy Jr. leading HHS under the Trump administration, the pharmaceutical industry finds itself under a microscope. Kennedy has frequently criticized the influence of "Big Pharma" and has pledged to reform drug pricing and transparency. This dispute presents a critical test for the administration’s "Make America Healthy Again" agenda, which balances a pro-business, deregulatory stance with a populist commitment to lowering healthcare costs for the average American.
Eli Lilly, for its part, remains steadfast. The company disclosed that while 50 large systems are currently being penalized, more than 2,300 other hospitals—representing roughly 70% of participants—have already complied with the data-sharing request. Lilly executives argue that the transparency provided by this data is the only way to ensure the integrity of the program. "We are committed to the 340B program and the providers it serves, but we cannot continue to subsidize a system that lacks basic oversight and results in unlawful duplicate discounts," a company spokesperson said in a statement. The company claims that the 50 targeted systems are "outliers" that are resisting common-sense transparency measures.
The financial implications of this standoff are immense. For many large urban hospital systems, 340B discounts represent tens of millions of dollars in annual savings. These funds are often used to subsidize uncompensated care, provide free transportation for patients, fund oncology programs in underserved areas, and lower the out-of-pocket costs of insulin and other life-saving medications. If Eli Lilly—a dominant player in the insulin and weight-loss drug markets—is allowed to maintain these restrictions, hospital administrators fear a domino effect where other major manufacturers follow suit, effectively dismantling the financial bedrock of the safety-net system.
Hospitals argue that the data Lilly is requesting is proprietary, administratively burdensome to produce, and potentially in violation of patient privacy regulations if handled improperly. Furthermore, hospital advocacy groups, such as 340B Health, argue that the "duplicate discount" problem is vastly overstated by the industry. They point to existing state-level mechanisms and HRSA audits designed to prevent such occurrences. "This is not about preventing duplicate discounts; it is about data mining and creating hurdles to reduce the number of discounts the company has to pay out," said a representative for a major hospital association.
The legal history of the 340B program provides a complex backdrop to this current fight. In May 2024, a U.S. Court of Appeals for the District of Columbia Circuit issued a ruling that gave pharmaceutical companies some leeway in how they distribute drugs through "contract pharmacies"—third-party pharmacies that dispense drugs on behalf of 340B hospitals. However, that ruling did not explicitly address whether a manufacturer could mandate data sharing as a prerequisite for the discounts themselves. The lawmakers’ letter to Secretary Kennedy suggests that Eli Lilly is overstepping the boundaries established by that court ruling and is attempting to create a new regulatory framework without congressional or HRSA approval.
The bipartisan nature of the congressional letter highlights the unique political position of the 340B program. While many Republicans generally favor deregulation, the program is vital to rural hospitals in GOP-leaning districts, many of which are on the brink of closure. Democrats, meanwhile, view the program as a cornerstone of the healthcare safety net. This alignment creates a powerful voting bloc that is difficult for the pharmaceutical lobby to overcome.
As the Trump administration weighs its response, the pharmaceutical industry is watching closely. If Secretary Kennedy and HHS take a hardline stance against Eli Lilly, it could signal a new era of aggressive federal oversight of drug manufacturers. Conversely, if the administration sides with Lilly’s calls for "transparency," it could embolden the industry to implement even stricter controls over how and where discounted drugs are distributed.
Market analysts note that Eli Lilly’s aggressive posture comes at a time of record-breaking profits for the company, driven largely by the success of its GLP-1 medications, Mounjaro and Zepbound. The irony of a company reporting multi-billion dollar quarterly earnings while cutting discounts for charity hospitals is not lost on the lawmakers. "At a time of unprecedented profitability, Eli Lilly’s attempt to squeeze more money out of the 340B program is both legally questionable and morally indefensible," the congressional letter concludes.
The dispute also raises broader questions about the future of drug pricing in America. With the Inflation Reduction Act’s (IRA) drug price negotiation provisions still a major point of contention between the industry and the government, the 340B program has become one of the few remaining levers the government can pull to ensure affordability for certain populations. Any erosion of the program is seen by healthcare advocates as a direct threat to the broader goal of lowering healthcare costs.
In the coming weeks, HHS is expected to issue a formal response or potentially initiate an administrative dispute resolution (ADR) process. The ADR process was recently revamped to handle such conflicts more efficiently, but its effectiveness remains untested in a case of this magnitude. If the administration fails to act, the lawmakers have hinted at legislative remedies, including potential amendments to the 340B statute that would explicitly prohibit manufacturers from placing conditions on the availability of discounts.
For now, the 50 hospital systems in the crosshairs of Eli Lilly’s policy are left in a state of financial uncertainty. Many are already seeing the impact on their bottom lines as they are forced to purchase Lilly’s medications at wholesale acquisition costs—which can be several times higher than the 340B price. The outcome of this battle will not only determine the fate of these specific price breaks but will also set a precedent for the entire pharmaceutical industry’s relationship with the American healthcare safety net for years to come. As the 2026 midterms approach, the pressure on the Trump administration to deliver a "win" for patients and hospitals over corporate interests will only intensify, making this a pivotal moment for Robert F. Kennedy Jr.’s tenure at HHS.
